Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
Date:3/6/2008

SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2007 financial results after the close of market on Wednesday, March 12, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a corporate overview on Wednesday, March 12, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-681-3375 (domestic) or 719-325-4913 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadenceph
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
2. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
8. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
11. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The November 2014 issue of ... open access journal featuring the following articles:, ... preserve photoresponsiveness in the retina , DNA ... hybridization using chromogenic substrates in zebrafish , ... protein electrophoresis , Nuclear LC3-positive puncta in ...
(Date:11/21/2014)... Angeles, CA (PRWEB) November 21, 2014 ... it that makes Albert Einstein so instantly recognizable? Why ... African-born physicist, mathematician, astronomer and author Hilton Ratcliffe seeks ... they have nothing at all to do with science. ... Muse Harbor Publishing , November 21, 2014), Ratcliffe puts ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... and in-depth research report on the transformer market. ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... economic situation analysis. The report also covers information ...
(Date:11/21/2014)... Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. ... that it has closed a brokered private placement ... approximately C$3.7 million.  Cormark Securities Inc. and Clarus ... Brokered Offering for a syndicate of agents that ... Corp. (collectively the "Agents"). Concurrently with the Brokered ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... and Europe, Reported Net Sales of $76.5 Million ... Company Revises Revenue Guidance Upward and Expense Guidance Downward,and ... Progress in Hematology, Oncology, Transplant, Neurology, Third Quarter ... sales of $76.5 million in Q3,2008 consisted of $71.2 ...
... visualizing vast networks of information and deepening understanding of content. ... ... (PRWEB) October 23, 2008 -- TheBrain® Technologies, the leading provider ... on its social networking site to connect the dots between ...
... A multi-institution team, funded by the National Human Genome ... (NIH), today reported results of the largest effort to ... most common form of lung cancer, lung adenocarcinoma. The ... approaches for detecting and treating the nation,s leading cause ...
Cached Biology Technology:Alexion Reports Third Quarter 2008 Results 2Alexion Reports Third Quarter 2008 Results 3Alexion Reports Third Quarter 2008 Results 4Alexion Reports Third Quarter 2008 Results 5Alexion Reports Third Quarter 2008 Results 6Alexion Reports Third Quarter 2008 Results 7Alexion Reports Third Quarter 2008 Results 8Alexion Reports Third Quarter 2008 Results 9Alexion Reports Third Quarter 2008 Results 10Alexion Reports Third Quarter 2008 Results 11Alexion Reports Third Quarter 2008 Results 12Alexion Reports Third Quarter 2008 Results 13Alexion Reports Third Quarter 2008 Results 14MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 2MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 3MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 4Large-scale genetic study sheds new light on lung cancer 2Large-scale genetic study sheds new light on lung cancer 3Large-scale genetic study sheds new light on lung cancer 4Large-scale genetic study sheds new light on lung cancer 5
(Date:11/7/2014)... -- In conjunction with the Glendale and ... of the Verdugos has announced the " GLENDALE ... initiative to keep the Verdugo Regional Crime Lab operational after ... of existence, the Lab has processed more than 400 DNA ... "Because our number one priority is the wellbeing ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... of death at the right time might actually help ... that could help in understanding animal populations, pest control ... paper in the journal Trends in Ecology and ... conclude that the kind of positive population effect an ... mortality, depends on the size and developmental stage of ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... global warming and instead reduce fossil-fuel use for the sake ... one from the University of Washington and one from the ... the current issue of the journal Nature (Jan. ... will trump the environment as a reason to curb the ...
... that certain photosynthetic ocean bacteria need to beware of ... carrying genetic material taken from their previous bacterial hosts ... machinery to activate the genes, a process never before ... occurs when a grifter virus injects its DNA into ...
... public information officers can now register online to the ... The meeting brings together over 10,000 scientists from all ... Earth, planetary, and space sciences. EGU,s General Assembly ... learn about recent developments in topics as diverse as ...
Cached Biology News:Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3Viruses con bacteria into working for them 2Viruses con bacteria into working for them 3European Geosciences Union General Assembly, April 22-27, 2012, Vienna, Austria 2
... of the smallest thermal cyclers on the market, ... the 0.5ml (20 samples) or 0.2ml microtube (25 ... heating and cooling rate of 3.6C/sec and 2.0C/sec ... Fast track programming with new quick dial ...
... The new TC-412 thermal cycler, flexible on ... TC-412 is a high performance, high sample throughput ... Features: , Flexible block format: The truly ... be exchanged in a matter of seconds without ...
... Provides a buffered anti-freeze environment for ... Maintains a liquid, low viscosity solution at ... is necessary and sampling is convenient ... during long-term storage Protect enzyme conjugates ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
Biology Products: